The role of ropeginterferon alfa-2b in the management of polycythaemia vera in SG

MIMS Oncology explores the current landscape of polycythaemia vera management in Singapore and the role of the newly launched ropeginterferon alfa-2b in improving patient outcomes. During an interview, Dr Dawn Mya, a leading haematologist practicing at Parkway Cancer Centre, Singapore, provides expert insights into the therapeutic potential of this novel treatment.